LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

AZN

188.47

+3.03%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

AZN

188.47

+3.03%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

AZN

188.47

+3.03%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

AZN

188.47

+3.03%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

AZN

188.47

+3.03%↑

Home・Akciju saraksts・Ventyx Biosciences Inc

Ventyx Biosciences Inc

Slēgts

13.99

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

13.99

Max

13.99

Galvenie mērījumi
By Trading Economics
Ienākumi	4.2M -23M
Darbinieki	83
EBITDA	6.6M -23M

Rekomendācijas
By TipRanks
Rekomendācijas	Neitrāls
Prognoze 12 mēnešiem	-4.43% downside

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	418M 1B
Iepriekšējā atvēršanas cena	13.99
Iepriekšējā slēgšanas cena	13.99

Ventyx Biosciences Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 12. marts 23:12 UTC

Karstas akcijas

Stocks to Watch: Adobe, Mission Produce, Buzzfeed, Ulta

2026. g. 12. marts 22:15 UTC

Peļņas

Wheaton Precious Metals Logs Higher 4Q Net Income, Boosts Dividend 18%

2026. g. 12. marts 21:42 UTC

Galvenie ziņu notikumi

Stryker Says Cyberattack Disruption Is Continuing

2026. g. 12. marts 21:29 UTC

Galvenie ziņu notikumi

Correction to War in Iran May Upend Brazil Central Bank's Plans Article

2026. g. 12. marts 21:27 UTC

Peļņas

Adobe CEO to Depart as AI Boosts Sales -- Update

2026. g. 12. marts 20:46 UTC

Peļņas

Adobe Posts Higher Sales With CEO Set to Depart

2026. g. 12. marts 20:21 UTC

Galvenie ziņu notikumi

Soybean Futures Higher on Instability in Iran --Daily Grain Highlights

2026. g. 12. marts 23:57 UTC

Tirgus saruna

Gold Edges Higher Amid Ongoing Middle East Conflict -- Market Talk

2026. g. 12. marts 23:38 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 12. marts 23:38 UTC

Tirgus saruna

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

2026. g. 12. marts 22:13 UTC

Peļņas

Orient Overseas: Tariff Measures, Trade Tensions Weighed on Results >0316.HK

2026. g. 12. marts 22:13 UTC

Peļņas

Orient Overseas: Middle East Situation Have Added to Future Uncertainity >0316.HK

2026. g. 12. marts 22:13 UTC

Peļņas

Orient Overseas: Charter Market Remains Exceptionally Tight With Vessels in Short Supply >0316.HK

2026. g. 12. marts 22:13 UTC

Peļņas

Orient Overseas 2025 Rev $9.72B Vs. $10.70B >0316.HK

2026. g. 12. marts 22:13 UTC

Peļņas

Orient Overseas 2025 Net $1.51B Vs. Net $2.58 >0316.HK

2026. g. 12. marts 22:13 UTC

Tirgus saruna

Peļņas

Global Equities Roundup: Market Talk

2026. g. 12. marts 22:13 UTC

Tirgus saruna

Peļņas

Adobe Says Customers Want to Try AI Products for Free First -- Market Talk

2026. g. 12. marts 21:16 UTC

Iegādes, apvienošanās, pārņemšana

Alexander & Baldwin: JV Formed by Affil of MW Group and Funds Affiliated With Blackstone and DivcoWest Completed Acquisition of All Outstanding A&B Common Shrs >ALEX

2026. g. 12. marts 21:04 UTC

Peļņas

Adobe Earnings Beat Is Overshadowed by CEO Departure. The Stock Is Sliding. -- Barrons.com

2026. g. 12. marts 21:02 UTC

Peļņas

Wheaton Precious Metals 4Q Adj EPS $1.22 >WPM

2026. g. 12. marts 21:02 UTC

Peļņas

Wheaton Precious Metals 4Q Sales $865M >WPM

2026. g. 12. marts 21:02 UTC

Peļņas

Wheaton Precious Metals 4Q Net $558.3M >WPM

2026. g. 12. marts 21:02 UTC

Peļņas

Wheaton Precious Metals 4Q EPS $1.23 >WPM

2026. g. 12. marts 20:57 UTC

Tirgus saruna

Galvenie ziņu notikumi

No Need For Canada Rate Increases Amid Jump in Bond Yields -- Market Talk

2026. g. 12. marts 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 12. marts 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 12. marts 20:15 UTC

Iegādes, apvienošanās, pārņemšana

Eaton Completes Acquisition Of Leading Liquid-cooling Solutions Provider Boyd Thermal, Creating An Industry-leading Grid-to-chip Solution For Data Centers >ETN

2026. g. 12. marts 20:10 UTC

Peļņas

Adobe Sees 2Q Rev $6.43B-$6.48B >ADBE

2026. g. 12. marts 20:05 UTC

Peļņas

Adobe 1Q Rev $6.4B >ADBE

2026. g. 12. marts 20:05 UTC

Peļņas

Adobe Sees 2Q Adj EPS $5.80-Adj EPS $5.85 >ADBE

Salīdzinājums

Cenas izmaiņa

Ventyx Biosciences Inc Prognoze

Cenas mērķis

By TipRanks

-4.43% uz leju

Prognoze 12 mēnešiem

Vidējais 13.38 USD -4.43%

Augstākais 14 USD

Zemākais 9 USD

Pamatojoties uz 8 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Ventyx Biosciences Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Neitrāls

8 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 8 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Ventyx Biosciences Inc — pēdējo 3 mēnešu laikā.

Finanšu rādītāji

Par Ventyx Biosciences Inc

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.